Novo Nordisk Reduces Wegovy Prices, Yet Affordability Remains Issue

Novo Nordisk has announced a significant reduction in the price of its weight-loss drug Wegovy, cutting the monthly cost for uninsured patients to $349, down from $499. This change is part of a broader effort to improve access to obesity treatments, although health professionals warn that affordability continues to be a major barrier for many patients.

As of Monday, higher doses of Wegovy will be available for $349 a month, aligning with a drug pricing strategy discussed earlier this month by the administration of former President Donald Trump. In addition, Novo Nordisk is offering a promotional rate of $199 per month for the first two months for patients using low doses of Wegovy and its diabetes counterpart, Ozempic. These new prices will be accessible at pharmacies across the country, through home delivery, and various telemedicine services.

Meanwhile, competitor Eli Lilly has also indicated plans to reduce prices for its own weight-loss drug, Zepbound, once a new multi-dose pen is launched. The company intends to offer an introductory dose at $299, with subsequent doses priced up to $449, reflecting a $50 decrease from the current rates for direct sales.

Challenges of Affordability Persist

Despite these reductions, affordability remains a pressing concern for many patients. A recent survey conducted by the nonprofit KFF revealed that nearly half of individuals using these treatments find them difficult to afford. Stacie Dusetzina, a professor at Vanderbilt University Medical Center and expert on prescription drug pricing, noted that people struggle to pay for medications once costs exceed $100 per month. She emphasized that the new pricing from Novo Nordisk may not significantly impact those with limited disposable income.

Furthermore, Dr. Laura Davisson, an obesity specialist at West Virginia University, pointed out that patients on Medicaid in certain states are still unable to access these medications due to lack of coverage. “We’ve seen hundreds of people lose coverage over the last few years, and the trend is concerning,” she stated. Dr. Davisson mentioned that her practice has initiated a support program for those losing access to treatment.

Looking ahead, there is potential for improved coverage for obesity treatments. Starting next year, the federally funded Medicare program will begin covering treatments for individuals with severe obesity and those who are overweight with related health issues. Qualifying patients will pay a $50 copay for the medication. This initiative is expected to increase access to Wegovy and similar treatments for many Americans.

Industry Response and Future Developments

According to Dave Moore, executive vice president for U.S. operations at Novo, around 40 million additional Americans may gain access to Wegovy due to these coverage expansions through Medicare and Medicaid. Currently, Medicaid programs in 20 states do provide coverage for obesity treatment.

While both Novo Nordisk and Eli Lilly have announced pricing adjustments, neither company has confirmed plans for further price reductions. In addition, both firms are pursuing the approval of oral versions of their medications, which would come with separate pricing structures.

A spokesperson for Eli Lilly, Courtney Kasinger, emphasized the importance of equitable coverage for obesity treatments, akin to those for chronic conditions. “We are committed to enhancing coverage across all stakeholders,” she said.

As the landscape for weight-loss medications continues to evolve, the focus will remain on making these essential treatments more accessible and affordable for those who need them most.